|
Found 16 result(s) FROM 1963 pages containing the term 'calcitonin'.
Monday Aug 25, 2008
Emisphere Reports Full Recruitment of Study Evaluating Eligen® Technology and Salmon Calcitonin on Vertebral Fractures in Postmenopausal Women
Emisphere Technologies announced that recruitment is finished for a randomized, double-blind, placebo-controlled, multicenter study of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D...
Monday Jun 23, 2008
More Zoledronic Acid Fracture Reduction Data Reported at Endocrine Society Meeting
Yearly infusions of zoledronic acid 5 mg reduced fractures and increased bone mineral density (BMD) when administered with or without concomitant osteoporosis therapy…
Monday Jun 09, 2008
Genta Announces Phase I Clinical Trial Results for G4544, an Oral Formulation of Gallium Nitrate, a Novel Potent Drug for Bone Disease
Results from the phase I clinical trial of G4544 showed that the drug was well-tolerated and that blood levels were achieved in a range known to be clinically bioactive...
Thursday Jun 05, 2008
Less Osteoporosis Care, More Hip Fractures Seen in Europe vs Other Countries
European doctors are less likely to screen for or treat osteoporosis, and hip fracture rates in Europe are higher than in North America or Australia, according to baseline data from the ongoing Global Longitudinal registry of Osteoporosis in Women (GLOW)…
Thursday Nov 29, 2007
New Method Provides Quick Estimate of 5-Year Hip Fracture Risk
A new algorithm based on 11 clinical factors can predict 5-year risk for hip fracture in postmenopausal women...
Tuesday Nov 13, 2007
Single Botulinum Toxin Injection Smooths Out OA Shoulder Pain
A single intra-articular injection of botulinum toxin type A relieved shoulder pain for a month in patients with refractory OA...
Thursday Aug 30, 2007
Vitamin K2 Supplements Protect Bone Architecture
Three years of dietary supplementation with vitamin K2 maintained bone strength and architecture despite having little effect on BMD...
Thursday Aug 09, 2007
Calcitonin Study Heightens Interest in Antiresorptive Agents to Prevent OA Joint Damage
Calcitonin prevents the development of OA in an animal model and adds to evidence that antiresorptive agents can protect both cartilage and bone...
Thursday Mar 15, 2007
Unigene Receives $5.5 Million Milestone Payment for Calcitonin Collaboration in Initiation of Osteoporosis Phase III Clinical Trial
Unigene Laboratories, Inc, a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs, announced that the initiation of a phase III clinical study conducted by Nordic Bioscience, the development partner with Novartis Pharmaceuticals AG, to treat osteoporosis with oral calcitonin has triggered a $5.5 million milestone payment due from Novartis to Unigene...
Monday Mar 12, 2007
Novartis, Nordic Bioscience to Initiate Osteoporosis Phase III Program Using Emisphere's EligenR Technology for Oral Salmon Calcitonin
Emisphere Technologies, Inc, a biopharmaceutical company pioneering the oral delivery of otherwise injectable drugs, announces that Novartis Pharmaceutical AG and its development partner Nordic Bioscience A/S will initiate a phase III clinical trial for the treatment of osteoporosis with an oral form of salmon calcitonin (SMC021), a new drug candidate, using Emisphere's eligen® delivery technology...
Thursday Mar 02, 2006
Denosumab Shows Promise in Phase II Study of Bone Mineral Density
Twice yearly injections of denosumab (previously known as AMG 162) significantly increased bone mineral density in the total hip, lumbar spine, distal 1/3 radius, and total body of postmenopausal women compared with placebo... McClung MR, et al. N Engl J Med. 2006;354:821-831.
Wednesday Jan 04, 2006
Oral Calcitonin May Delay Onset of Joint Disease and Relieve Pain of OA
Although calcitonin is an established antiresorptive agent, new research suggests that it also has a role in chondroprotection and may help relieve symptoms accompanying joint disease... Sondergaard BC, et al. Presented at: 10th World Congress of the Osteoarthritis Research Society International (OARSI); December 8–11, 2005; Boston, Mass. Abstract P133.
Wednesday Dec 14, 2005
Emisphere's Oral Drug Delivery Technology (Eligen®) Successful With Oral Salmon Calcitonin for Osteoarthritis
Emisphere Technologies, Inc, of Tarrytown, New York, has announced that an independent pilot study of daily salmon calcitonin therapy...
Sunday Aug 21, 2005
Unigene's Calcitonin-Salmon Nasal Spray Approved for Osteoporosis in US
Unigene Laboratories, Inc, and Upsher-Smith Laboratories, Inc, announced FDA approval of their nasal calcitonin product...
Thursday Jul 21, 2005
Nastech's Intranasal PTH1-34 Peptide in Phase I for Osteoporosis
Nastech Pharmaceutical Company Inc. of Bothell, Washington, announced the start of a second clinical study to determine the pharmacokinetics and safety of its investigational intranasal human parathyroid hormone (PTH1-34) drug for the treatment of osteoporosis.
Friday Jun 11, 2004
Pain Management Remains a Key Component to Treatment of Inflammatory Conditions
Understanding the mechanisms involved in chronic pain and treating it as effectively as possible is a crucial component to the management of rheumatoid arthritis and other inflammatory disease...
|
